pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,093 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT824Endpoints620BioPharma Dive237onclive165Fierce Biotech90BioSpace87raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • Celcuity strengthens case for ASCO-spotlighted breast cancer drug
    The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.
    BioPharma Dive · 2mo ago↗ source
  • Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies
    The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that had threatened to upend one of the main ways abortion is provided across the…
    STAT · 2mo ago↗ source
  • Researchers urge study of paternal deaths, though a new paper finds fatherhood is protective
    A research letter published on Monday in JAMA Pediatrics argues that paternal mortality deserve more attention
← prev
page 39 of 44
next →
21
fda recalls20
fda medwatch17
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
STAT · 2mo ago
↗ source
  • STAT+: Pump the brakes on AI, buddy; and deposition deadlock
    It's tough to write nuanced headlines, but a new study on AI in emergency rooms is getting way overhyped.
    STAT · 2mo ago↗ source
  • With $97M, Latus pursues a different kind of Huntington’s gene therapy
    The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.
    BioPharma Dive · 2mo ago↗ source
  • UCB to acquire maker of antibody treatments for autoimmune diseases
    A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
    STAT · 2mo ago↗ source
  • What to know about hantavirus, the illness suspected in a cruise ship outbreak
    A rodent-borne illness is suspected of causing an outbreak aboard a cruise ship that has killed three people and sickened others. Here's what to know about hantavirus.
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news
    Two drugmakers asked the U.S. Supreme Court to restore mail-order access to the abortion pill mifepristone, after an appeals court suspended deliveries
    STAT · 2mo ago↗ source
  • Federal court blocks mailing of mifepristone
    Longevity "blue zones," an update on uterine transplant science, and more Morning Rounds health news
    STAT · 2mo ago↗ source
  • STAT+: Biotech raises $42 million to run Huntington’s disease trial
    Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's disease.
    STAT · 2mo ago↗ source
  • UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
    The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.
    BioPharma Dive · 2mo ago↗ source
  • What is your AI drug repurposing strategy missing?
    Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.
    BioPharma Dive · 2mo ago↗ source
  • Immigration changes are driving foreign researchers to leave the U.S. — or not come to begin with
    Labs are seeing fewer applications from international students and researchers, and some doctoral students are considering leaving early.
    STAT · 2mo ago↗ source
  • Opinion: Are blue zones real? Answering that question is harder than ever
    "Blue zones" as a concept have strayed far and wide from their humble roots, write Shelley Wood and Eric Topol.
    STAT · 2mo ago↗ source
  • Opinion: STAT+: China’s strict new supply chain regulations could create massive problems for Western biopharma companies
    China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.
    STAT · 2mo ago↗ source
  • Federal appeals court blocks mailing of abortion pill mifepristone
    Mifepristone, involved in most abortions in the U.S., can now be distributed only in person and at clinics.
    STAT · 2mo ago↗ source
  • Opinion: What do medical students think about their education?
    “No one's pulling the pieces together”: a conversation with medical students about preventive care education.
    STAT · 2mo ago↗ source
  • Opinion: STAT readers on MAHA activists, perimenopause, and diversity in medical school
    “Unfortunately, the resources don't exist to take every flat-earther to the International Space Station to change their mind,” a STAT reader writes.
    STAT · 2mo ago↗ source
  • Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
    Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and…
    STAT · 2mo ago↗ source
  • Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
    Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…
    BioPharma Dive · 2mo ago↗ source
  • Moderna sees revenue bump from international COVID vaccine sales
    The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.
    BioPharma Dive · 2mo ago↗ source
  • Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
    Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Axsome wins FDA nod for Alzheimer’s agitation
    Vinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The Readout
    STAT · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more
    The FDA proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be used for compounded versions
    STAT · 3mo ago↗ source